General American Investors Co. Inc. Boosts Stock Holdings in Maravai LifeSciences Holdings, Inc. $MRVI

General American Investors Co. Inc. raised its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 8.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,716,193 shares of the company’s stock after buying an additional 130,877 shares during the quarter. General American Investors Co. Inc. owned about 0.67% of Maravai LifeSciences worth $4,857,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP purchased a new stake in shares of Maravai LifeSciences during the 4th quarter valued at approximately $7,670,000. Millennium Management LLC grew its holdings in Maravai LifeSciences by 308.7% during the 4th quarter. Millennium Management LLC now owns 1,797,052 shares of the company’s stock valued at $5,840,000 after buying an additional 1,357,349 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of Maravai LifeSciences by 299.0% in the fourth quarter. First Eagle Investment Management LLC now owns 1,799,336 shares of the company’s stock valued at $5,848,000 after acquiring an additional 1,348,405 shares during the period. Marshall Wace LLP increased its holdings in Maravai LifeSciences by 52.3% during the 4th quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock worth $6,501,000 after acquiring an additional 687,253 shares during the period. Finally, Tejara Capital Ltd lifted its stake in Maravai LifeSciences by 23.1% in the 4th quarter. Tejara Capital Ltd now owns 3,020,209 shares of the company’s stock worth $9,816,000 after purchasing an additional 566,768 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Trading Up 2.0%

Shares of MRVI traded up $0.12 during mid-day trading on Friday, hitting $6.09. 4,388,991 shares of the company’s stock traded hands, compared to its average volume of 2,776,341. The business’s 50-day moving average price is $5.03 and its 200-day moving average price is $3.94. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.99 and a 1 year high of $6.55. The firm has a market capitalization of $1.57 billion, a P/E ratio of -8.58 and a beta of 0.65. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative net margin of 51.07% and a negative return on equity of 17.87%. The business had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. As a group, sell-side analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Insider Activity

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the completion of the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. This represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MRVI shares. UBS Group restated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Wells Fargo & Company upped their price objective on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a report on Friday, May 8th. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Wall Street Zen raised shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $6.00 price objective on shares of Maravai LifeSciences in a report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Maravai LifeSciences has an average rating of “Hold” and an average price target of $5.50.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.